01:59 PM EDT, 10/16/2024 (MT Newswires) -- Bright Minds Biosciences ( DRUG ) said Wednesday that its BMB-201 proprietary compound showed similar efficacy to morphine in preclinical pain models.

Higher doses resulted in "significant" therapeutic effect, with female rodents experiencing improved pain relief and guarding behavior, the company said.

The company said it plans to advance BMB-201 into clinical trials to further assess its safety and efficacy in humans.

Bright Minds added that it is eying to position BMB-201 as a non-opioid alternative for neuropathic pain relief, saying its efficacy indicates it may provide better pain relief compared with traditional opioid treatments without the related risks of dependency and side effects.

Shares were down more than 19% in recent trading.

Price: 30.97, Change: -7.52, Percent Change: -19.54